The U.S. Food and Drug Administration (FDA) has reportedly issued a severe rebuke against uniQure N.V., accusing the biotechnology firm of presenting "distorted" and "manipulated" clinical data. The allegations center on the company's experimental drug AMT-130, which federal health officials have characterized as a "failed" treatment. In response to these developments, the law firm Hagens Berman has announced an update to its ongoing investigation into a securities class action lawsuit against the company. The investigation seeks to determine whether uniQure misled investors regarding the efficacy and regulatory status of its key drug candidate. This regulatory scrutiny represents a significant blow to the company's credibility and its future prospects in the gene therapy market. Market analysts expect these accusations to exert substantial downward pressure on the stock as legal and regulatory risks escalate.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis